Evidence map›Paper›PMID 40705617›Full record

ArticleExperimental and clinical psychopharmacology2025

Self-reported changes and experiences with substance use among real-world patients treated with medical ketamine.

Shahar Almog, Maribel Rodriguez Perez, Deepthi S Varma, Alexia N Obrochta, Michelle Weiner, JeeWon Cheong, Meredith S Berry

Abstract read
In one paragraph

Article in Experimental and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shahar AlmogDepartment of Health Education and Behavior, University of Florida.ORCID 0000-0003-3093-3947
Maribel Rodriguez PerezDepartment of Health Education and Behavior, University of Florida.ORCID 0009-0003-2280-4595
Deepthi S VarmaDepartment of Epidemiology, University of Florida.ORCID 0000-0003-1163-0377
Alexia N ObrochtaDepartment of Health Education and Behavior, University of Florida.ORCID 0009-0008-7629-4080
Michelle WeinerNeuroPain Health.
JeeWon CheongDepartment of Health Education and Behavior, University of Florida.ORCID 0000-0001-6033-7180
Meredith S BerryDepartment of Health Education and Behavior, University of Florida.ORCID 0000-0002-5526-7437

Funding

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect DeterminationK01DA052673 · NIDA · UNIVERSITY OF FLORIDA · PI Meredith Berry · 2022 to 2026
$916k
The potential of oxytocin to reduce opioid abuse liability and pain among older adultsR21DA056813 · NIDA · UNIVERSITY OF FLORIDA · PI BERRY, MEREDITH, CRUZ-ALMEIDA, YENISEL · 2023 to 2024
$419k
National Institutes of Health; National Institute on Drug AbuseNIDA NIH HHS K01 DA052673NIDA NIH HHS R21 DA056813Source Research Foundation
6 · The paper itself

Abstract

Ketamine is increasingly used in community clinics as a long-term treatment for different psychiatric and pain conditions, including substance use disorders. Data are lacking, however, regarding the potential influence of ketamine on other substance use. In this secondary analysis, we aimed to explore the relationship between medical ketamine and other substance use among real-world patients by combining quantitative and qualitative data. In an online anonymous pilot survey (

Indexed as

KetamineSubstance-Related DisordersAdultFemaleHumansMaleMiddle AgedPilot ProjectsSelf ReportSurveys and QuestionnairesYoung AdultKetamine

Identifiers

PMID40705617
PMCPMC12554366

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.